Table 2.
Case | Age at ATL diagnosis, y | Time in cohort, y | Place of birth | Ethnic group | HIV serology | Observed HTLV-1 seroconversion | ATL subtype | Status (April 2018) | Survival time |
---|---|---|---|---|---|---|---|---|---|
1 | 26 | 5.6 | Surinam | NM | Negative | No | Lymphoma | Dead | 0 d |
2 | 45 | 7.3 | French Guiana | NM | Negative | No | Lymphoma | Unknown | Unknown |
3 | 47 | 8.6 | Surinam | NM | Negative | No | Lymphoma | Alive | >10 y |
4 | 29 | 14.7 | Surinam | NM | Negative | No | Acute | Dead | 3.5 mo |
5 | 54 | 15.7 | Surinam | NM | Negative | No | Acute | Dead | 4.6 mo |
6 | 51 | 18.6 | Surinam | NM | Negative | No | ND | Dead | 6.6 mo |
7 | 52 | 19.9 | Surinam | NM | Negative | No | Acute | Dead | 3.9 mo |
8 | 39 | 21.4 | Surinam | ND | Negative | No | Lymphoma | Dead | 1.0 mo |
9 | 59 | 25.8 | Surinam | NM | Negative | No | Acute | Dead | 0.1 mo |
ND, not determined; NM, Noir Marron.